Arpeggio Biosciences develops a proprietary platform that reads nascent RNA to monitor transcription and screens drug libraries for effects on thousands of gene and non-coding transcripts. Its assay combined with machine-learning algorithms can monitor activity of more than 100,000 transcripts and reconstruct biological networks to match molecules to diseases. The company has built what it describes as the largest database of nascent-RNA sequences and focuses on discovering modulators of high-value targets considered "undruggable," such as transcription factors. Arpeggio's platform supports screening of small molecules, biologics, and antisense oligonucleotides and is designed to enable modulation of an entire cellular transcriptome rather than single targets. The company is preclinical and plans to use the Series A financing to continue development of its drug pipeline and transcription-monitoring technologies. Arpeggio Bio has developed an automated platform that collects high‑resolution time‑series RNA profiles and applies proprietary machine learning to reconstruct the biological networks a drug affects. The company combines a proprietary biological assay with algorithms (originally developed for financial forecasting) to identify genes critical for drug success or failure. Arpeggio says its data elucidates drug and disease mechanisms to support development of safer, more effective therapies. Since its 2018 inception the company has partnered with over twenty biotech and pharmaceutical companies, including four of the world’s top ten. Funding announced will support ongoing development of a nascent RNA drug screen. The company’s founder and CEO, Joey Azofeifa, was named to the 2020 Forbes 30 Under 30 List in Healthcare.

Total raised

$20M

Funding rounds

2

Latest round

Series A

Latest activity

Sep 2022